ArticleAging medicine (Milton (N.S.W))2025
A Retrospective Study of First-Line Immunotherapy for Advanced Non-Small Cell Lung Cancer in the Elderly.
Article in Aging medicine (Milton (N.S.W)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The prognostic value of the pan-immune-inflammation value in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Morbidity Among the Aging Population in Northern Bangladesh: An Epidemiological Study.Aging medicine (Milton (N.S.W)) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: In this study, we compared the efficacy and safety of first-line IO among different age subgroups of elderly patients, as well as in comparison to non-elderly patients with advanced NSCLC. Additionally, we investigated hematological biomarkers associated with overall survival (OS) and compared the efficacy and safety of pembrolizumab plus chemotherapy (CT) versus tislelizumab plus CT in the treatment of advanced NSCLC. Methods: We conducted a retrospective analysis of clinical data from 298 patients with stage IIIB-IVB NSCLC without driver mutations who received first-line IO at The Second Xiangya Hospital of Central South University between June 1, 2019, and June 30, 2023. Differences between elderly and non-elderly patients, as well as among different elderly age subgroups, were analyzed using the chi-squared test and the Kruskal-Wallis Results: The study population was divided into two groups: elderly group (≥ 65 years old, Conclusion: Age may not be the main prognostic factor for the effectiveness of first-line immunotherapy in patients with advanced NSCLC. Longer mOS was observed in patients who were non-smokers, had no bone metastases, exhibited PD-L1 TPS ≥ 50%, and had a higher prognostic nutritional index (PNI), regardless of age. Furthermore, the efficacy and safety profiles of pembrolizumab plus CT versus tislelizumab plus CT show no differences in the treatment of advanced NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.